Altium Capital Management LP acquired a new stake in shares of REGENXBIO Inc. (NASDAQ:RGNX) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 62,317 shares of the biotechnology company’s stock, valued at approximately $2,421,000.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Virginia Retirement Systems ET AL acquired a new stake in REGENXBIO during the second quarter valued at approximately $237,000. Botty Investors LLC boosted its holdings in shares of REGENXBIO by 14.4% in the 2nd quarter. Botty Investors LLC now owns 287,136 shares of the biotechnology company’s stock worth $11,155,000 after acquiring an additional 36,078 shares in the last quarter. Stifel Financial Corp acquired a new position in shares of REGENXBIO in the 2nd quarter worth approximately $242,000. Blueshift Asset Management LLC acquired a new position in shares of REGENXBIO in the 2nd quarter worth approximately $441,000. Finally, Geode Capital Management LLC boosted its holdings in shares of REGENXBIO by 5.5% in the 2nd quarter. Geode Capital Management LLC now owns 662,708 shares of the biotechnology company’s stock worth $25,746,000 after acquiring an additional 34,771 shares in the last quarter. 77.85% of the stock is currently owned by institutional investors.
In other news, Director Allan M. Fox sold 48,233 shares of REGENXBIO stock in a transaction on Friday, September 17th. The shares were sold at an average price of $45.04, for a total transaction of $2,172,414.32. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Kenneth T. Mills sold 1,500 shares of REGENXBIO stock in a transaction on Monday, September 27th. The stock was sold at an average price of $42.19, for a total transaction of $63,285.00. The disclosure for this sale can be found here. 12.40% of the stock is owned by corporate insiders.
REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings results on Monday, August 9th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.08) by ($0.28). The company had revenue of $22.04 million during the quarter, compared to the consensus estimate of $21.17 million. REGENXBIO had a negative net margin of 90.05% and a negative return on equity of 31.31%. The firm’s revenue was up 33.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.91) earnings per share. Equities analysts anticipate that REGENXBIO Inc. will post -2.88 earnings per share for the current year.
Several analysts have commented on RGNX shares. Chardan Capital reiterated a “buy” rating and set a $100.00 target price on shares of REGENXBIO in a research report on Tuesday, August 10th. Barclays upped their price objective on shares of REGENXBIO from $79.00 to $82.00 and gave the company an “overweight” rating in a research report on Tuesday, September 14th. Zacks Investment Research cut shares of REGENXBIO from a “hold” rating to a “strong sell” rating in a research report on Friday, August 13th. SVB Leerink reaffirmed a “hold” rating on shares of REGENXBIO in a research note on Tuesday. Finally, Royal Bank of Canada upped their target price on shares of REGENXBIO from $50.00 to $55.00 and gave the stock a “sector perform” rating in a research note on Tuesday, September 14th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $60.63.
REGENXBIO, Inc is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors; and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381.
Recommended Story: Dollar Cost Averaging
Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for REGENXBIO Inc. (NASDAQ:RGNX).
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.